drugset / Trial / NCT06776679

A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants

NCT06776679

Phase 1 Completed 8 enrolled BeiGene
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the absorption, metabolism, and excretion of \[14C\]-BGB-16673 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.

Timeline

Start
2025-01-24
Primary completion
2025-03-27
Completion
2025-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BGB-16673 Other / unclassified Oral

Indications

No indication recorded.